Richter-Helm and Athera to Develop Recombinant Protein to Treat Cardiovascular Disease

February 11, 2009

Richter-Helm BioLogics GmbH & Co. KG (Hamburg, Germany) and Athera Biotechnologies AB (Stockholm, Sweden) have signed an agreement for the development and manufacturing of Annexin A5, Athera?s novel product for prevention of plaque rupture and athero-thrombosis.

Richter-Helm BioLogics GmbH & Co. KG (Hamburg, Germany) and Athera Biotechnologies AB (Stockholm, Sweden) have signed an agreement for the development and manufacturing of Annexin A5, Athera’s novel product for prevention of plaque rupture and athero-thrombosis.

Annexin A5 is produced using Richter-Helm’s proprietary E. coli–based expression system. Richter-Helm will initiate strain and process development of the new process to a 1,000 L production scale.

The recombinant protein Annexin A5 is intended for the treatment of patients with acute coronary syndrome and who are at imminent risk for myocardial Infarction.